glp-1 agonist diarrhea Your guide to side effects How to manage diarrhea related

Methods Literature was searched and perspectives from 10 healthcare professionals with experience in switching patients with T2D to OW semaglutide from another GLP1RA were collated

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting

Newer pharmacologic treatments for T2DM include glucagon-like peptide-1 receptor agonists and sodiumglucose cotransporter 2 inhibitors

26, e12953

Implications for telehealth companies and the weight loss drug market: There is a robust market of consumers willing to pay for weight loss drugs out of pocket

Most common side effects were gastrointestinal, with 24.5% of participants in the phase 2 obesity trial discontinuing efinopegdutide 10 mg due to AE however when the same dose was used with gradual escalation at the MASLD trial (starting dose 2.4 mg for 4 weeks, then 5 mg for 4 weeks and then 10 mg), only 5.6% of participants discontinued the medication due to AE